The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival ...

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future. Recently, the U.S. Food and Drug Administration (FDA) accepted ...

Tibetan tingsha bells are used as a brief pre-event grounding intervention, leveraging sustained high-frequency resonance to ...

For many facing a cancer diagnosis, the "why" can be the most elusive piece of the puzzle. When Lauren Yerkes was diagnosed ...

The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 ...

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...

Dr. Lakshmi Nayak, director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute, explained in an interview with ...

Closed, diagnosis-specific online communities provided psychologically safe space for young breast cancer survivors to ...

A mobile app–based self-acupressure program may help reduce cancer-related fatigue in women with ovarian cancer, according to Susanna M. Zick, professor in the Department of Family Medicine and ...

Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions. As the 2026 ASCO Genitourinary (GU) Cancers ...